Lista de obras -

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

artículo científico publicado en 2015

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

artículo científico publicado en 2011

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

artículo científico publicado en 2013

Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.

artículo científico publicado en 2010

ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1

artículo científico publicado en 2011

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

artículo científico publicado en 2015

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

artículo científico publicado en 2005

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

artículo científico publicado en 2016

High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype.

artículo científico publicado en 2010

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recur

artículo científico publicado en 2015

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials

artículo científico publicado en 2016

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

artículo científico publicado en 2016

Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance

artículo científico publicado en 2019

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

artículo científico publicado en 2010

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer

artículo científico publicado en 2015

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer

artículo científico publicado en 2018

Molecular biology of bladder cancer

artículo científico publicado en 2007

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations

artículo científico publicado en 2018

Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development

article

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

artículo científico publicado en 2006

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

artículo científico publicado en 2003

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50

artículo científico publicado en 2014

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

artículo científico publicado en 2013

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

artículo científico publicado en 2006

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.

artículo científico publicado en 2013

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition

artículo científico publicado en 2014

The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors

artículo científico publicado en 2006

β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.

artículo científico publicado en 2013

Lista de obras de

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.

ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recur

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer

Molecular biology of bladder cancer

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations

Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition

The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors

β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.